Quantum Biopharma Ltd. Files October 2024 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Oct 29, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory, foreign-private-issuer
TL;DR
Quantum Biopharma (formerly FSD Pharma) filed its Oct 6-K, CFO signed off.
AI Summary
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on October 29, 2024. The report is for the month of October 2024 and indicates the company is a foreign private issuer filing annual reports under Form 20-F. Donal Carroll, Chief Financial Officer, signed the report.
Why It Matters
This filing provides an update on Quantum Biopharma's regulatory reporting status and confirms its CFO, Donal Carroll, has signed off on the October 2024 disclosures.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and CFO signature, with no new material financial or operational information.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer of the report
- FSD Pharma Inc. (company) — Former name of the registrant
- Donal Carroll (person) — Chief Financial Officer who signed the report
- October 29, 2024 (date) — Date the report was filed
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public pursuant to the laws of its home country.
What was Quantum Biopharma Ltd. formerly known as?
Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc., with a date of name change on March 27, 2019.
Who signed the Form 6-K filing on behalf of Quantum Biopharma Ltd.?
The Form 6-K was signed by Donal Carroll, Chief Financial Officer, on October 29, 2024.
Which form does Quantum Biopharma Ltd. use for its annual reports?
Quantum Biopharma Ltd. files its annual reports under cover of Form 20-F.
What is the principal executive office address for Quantum Biopharma Ltd. in Canada?
The principal executive office address is 55 University Ave., Suite 1003, Toronto, Ontario M5J 2H7, Canada.
Filing Stats: 142 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-10-29 07:31:03
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 21KB
- fsd_ex991img2.jpg (GRAPHIC) — 8KB
- 0001654954-24-013416.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 29, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release 3